PAMA Reporting Is Over: How Independent Laboratories Can Prepare for 2027

Looking for laboratory billing software or RCM services? Visit our Laboratory Solutions page → to see how ADS supports labs like yours.

For the past several months, independent laboratories across the country have been focused on one milestone:the July 31 PAMA reporting deadline. Finance teams gathered private payer data, laboratory leadership reviewed reimbursement information, and billing departments submitted the required reporting to CMS under the Protecting Access to Medicare Act.

That was a significant effort, and it is done. Now laboratory executives are asking a different question. What happens next?

 

The answer is that this is one of the most important planning periods your laboratory has had in years. Whether Congress passes the RESULTS Act or the current reimbursement schedule moves forward, the laboratories that perform best in 2027 will be the ones that started preparing in 2026.

 

What happens after the PAMA reporting deadline?

CMS now reviews the private payer data submitted by applicable laboratories and uses it to calculate Clinical Laboratory Fee Schedule rates. Those rates take effect January 1, 2027.

 

The schedule between now and then is fixed. CMS posts proposed payment determinations for new and reconsidered codes in September 2026, followed by a public comment period. A public meeting and the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests convene September 15 and 16 to address codes for which CMS received no applicable information. Final determinations are posted in November 2026.

 

Under current law there is no phase-in reduction in 2026. Beginning January 1, 2027 and running through 2029, Medicare may not reduce payment for a test by more than 15 percent compared with the prior year. Roughly 800 codes are exposed.

 

That gives laboratory leaders about five months. Not to wait, but to work.

 

The road to 2027 starts today

Many laboratory leaders view July 31 as the finish line. It is the starting point.

 

Between now and January 1, 2027, laboratories have a genuine opportunity to evaluate financial performance, improve operational efficiency, and strengthen the parts of the business that are entirely within their control. No one knows exactly what Congress will do. Industry organizations continue supporting the RESULTS Act, legislation designed to modernize Medicare laboratory reimbursement by creating a more representative data collection process and reducing future volatility. The bill has bipartisan backing and more than 100 cosponsors, but it has not become law.

While that plays out, prepare for every scenario. The organizations that succeed rarely wait for someone else to solve their problems.

 

Focus on the revenue you already earned

One of the biggest opportunities we see is not future reimbursement. It is today's reimbursement.

Many independent laboratories lose significant revenue every month to denied claims, underpayments, coding errors, aging accounts receivable, and billing workflows that have not kept pace with changing payer requirements. Improving collections does not always require performing more tests. Often it requires improving the revenue cycle.

 

Recovering revenue you have already earned is one of the fastest ways to improve financial performance, and it does not depend on what happens in Washington.

 

Understand your financial exposure

Every laboratory should understand how future reimbursement changes could affect its business, and the exercise is simpler than most teams expect.

 

Pull your highest volume Medicare laboratory tests and model them against different reimbursement scenarios, including the maximum 15 percent reduction. Most laboratories have never run this number. The ones that have make faster and better decisions about staffing, technology investment, budgeting, and growth.

 

Preparation removes uncertainty. That is worth an afternoon.

 

Why does laboratory technology matter more than ever?

Laboratory billing has become considerably more complex, and payer rules are now differentiated by laboratory type. Independent laboratories specializing in molecular diagnostics, toxicology, pathology, genetics, and specialty testing each face distinct payer edits, documentation requirements, and reimbursement rules.

 

Generic billing systems were not designed for this environment. A process that cleared claims two years ago can produce consistent front-end denials today, not because the claims are wrong but because payer logic became more granular and the workflow did not follow.

 

Your billing platform should support your specialty, automate workflows, reduce manual effort, and give you visibility into financial performance. Just as important is the connection between systems. When the laboratory information system, billing, and revenue cycle management work together, laboratories spend less time correcting claims. That interface is where a surprising amount of laboratory revenue quietly disappears, and it is rarely the first place anyone looks.

 

Molecular and toxicology laboratories continue to grow

Reimbursement pressure receives most of the industry's attention, but the demand side of this business is healthy, and the federal data makes that clear.

 

According to the HHS Office of Inspector General, genetic testing accounted for 43 percent of all Medicare Part B laboratory spending in 2024, reaching $3.6 billion, up from 18 percent in 2018. Genetic tests made up roughly 5 percent of test volume while driving nearly half the dollars. Spending on non-genetic testing has generally declined since 2021.

 

Precision medicine, genetic testing, oncology diagnostics, and personalized medicine continue driving laboratory growth. Independent toxicology laboratories continue providing essential services despite reimbursement pressure and rising labor and reagent costs.

 

Success in these specialties depends on more than laboratory science. It requires clean claims, specialty-specific billing expertise, efficient workflows, and technology designed for laboratory medicine. Laboratories that convert growing volume into well-documented, promptly paid claims are in a strong position regardless of what the fee schedule does.

 

Partnership is more valuable than ever

Preparing for 2027 requires more than software. It requires experience.

 

For nearly 50 years, Advanced Data Systems has partnered with healthcare organizations to improve operational efficiency, strengthen revenue cycle performance, and modernize laboratory technology. Along the way we have built relationships throughout the laboratory industry.

 

If your laboratory needs expertise beyond software or revenue cycle management, we will connect you with trusted consultants, operational specialists, compliance experts, and industry partners. Partnership means helping laboratories solve business problems, not simply selling them products.

 

What will successful laboratories be doing between now and January?

The strongest laboratories over the next several years will not necessarily be the ones with the fewest reimbursement challenges. They will be the ones that used this window to improve every part of the business.

 

That means reviewing billing workflows, reducing denials, strengthening collections, evaluating payer performance, improving operational efficiency, investing in technology, and building relationships with experienced partners. These are investments that create value regardless of what happens in Washington.

 

Frequently asked questions

What happens after the PAMA reporting deadline?

CMS reviews the private payer data submitted by applicable laboratories and uses it to calculate Clinical Laboratory Fee Schedule rates that take effect January 1, 2027. Proposed determinations are posted in September 2026 and final determinations in November 2026.

Will the RESULTS Act stop PAMA reimbursement reductions?

The RESULTS Act has bipartisan support and more than 100 cosponsors but has not become law as of August 2026. Laboratories should prepare for the current reimbursement schedule while monitoring legislative activity.

How much can Medicare laboratory reimbursement drop in 2027?

Up to 15 percent per test compared with the prior year. The 15 percent annual cap applies from 2027 through 2029 under current law, and approximately 800 codes are affected.

How can laboratories prepare for 2027?

Model your highest volume CLFS codes at the maximum reduction, reduce denials, review payer contracts, improve billing workflows, and confirm your billing process matches your testing specialty.

Why is laboratory revenue cycle management important?

A strong laboratory revenue cycle reduces claim denials, improves collections, and increases reimbursement accuracy without increasing testing volume.

How can laboratory billing software improve reimbursement?

Laboratory billing software automates claims processing, improves coding accuracy, reduces billing errors, streamlines workflows, and provides financial visibility across the revenue cycle.

 

Looking ahead

The July 31 reporting deadline is behind us. The opportunity to strengthen your laboratory begins today.

 

Whether your organization is focused on revenue cycle management, laboratory billing software, molecular diagnostics, toxicology, operational efficiency, or simply getting ready for 2027, the decisions you make over the next several months will have a lasting effect on your laboratory's financial performance.

 

Advanced Data Systems has been helping healthcare organizations navigate change since 1977. We would be glad to help your laboratory prepare for what comes next.